Navigation Links
Vion Pharmaceuticals Reports 2009 Second Quarter And Six-Month Results
Date:8/11/2009

d the inability to continue operations as a result, and a variety of other risks set forth from time to time in Vion's filings with the Securities and Exchange Commission, including but not limited to the risks attendant to the forward-looking statements included under Item 1A, "Risk Factors" in Vion's Form 10-K for the year ended December 31, 2008, "Risk Factors" in Vion's Post-Effective Amendments on Form S-1 Registration Statement filed on March 23, 2009 and under Item 1A, "Risk Factors" in Vion's Form 10-Q for the quarter ended March 31, 2009. Except in special circumstances in which a duty to update arises under law when prior disclosure becomes materially misleading in light of subsequent events, Vion does not intend to update any of these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

    COMPANY CONTACT:  Vion Pharmaceuticals, Inc.
                      Alan Kessman, Chief Executive Officer
                      Howard B. Johnson, President & CFO
                      (203) 498-4210

                                VION PHARMACEUTICALS, INC.
                               (A Development Stage Company)

                      CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

                                          Three Months Ended  Six Months Ended
                                               June 30,           June 30,
    (In thousands, except per share data)  2009       2008    2009       2008
    -------------------------------------------------------------------------
                                              (Unaudited)        (Unaudited)

    Technology license fee revenue           $5      $13       $10        $27

    Operating expenses:
      Clinical trials                     1,590    2,953     2,611      5,807
      Other research and development      1,536  
'/>"/>
SOURCE Vion Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... In the key developed markets, the hypertension ... is set to decrease through 2020 at a negative CAGR ... expected up to 2017 at a 2.6% CAGR and a ... to the surging penetration of fixed-dose combination drugs like Azor, ... Benicar HCT, and Tekamlo), a hike in the prevalence population ...
(Date:3/26/2015)... March 26, 2015 In preparation for ... Fitness Revolution, founded by Samir Becic, has issued ... own personal health and fitness, as well as their ... The list includes Sen. Ted Cruz, who has officially ... as all other politicians who have shown interest in ...
(Date:3/26/2015)... March 26, 2015 With the rapidly ... role in managing their care, its not just doctors ... with no medical background want a piece of the ... has seen an increase in franchises purchased by people ... , Why Chiropractic? , Chiropractic is an exploding ...
(Date:3/26/2015)... The beauty industry united on Saturday, ... who revolutionized the business of beauty education. The Beauty ... of Pivot Point International, Inc. Passage’s wife Lenie, and ... Held at the Art Institute of Chicago, the sold-out ... and media leaders and served as the signature gala ...
(Date:3/26/2015)... March 26, 2015 LinkToBanking, a ... industries, names Tom Fleming as Chairman of the ... Board, effective immediately. With their combined knowledge ... services industry, Mr. Fleming and Mr. Casares will ... services to cannabis related businesses. , About Tom ...
Breaking Medicine News(10 mins):Health News:Top 8 Developed Anti-Hypertensive Therapeutics Markets Discussed in New GBI Research Report Published at MarketPublishers.com 2Health News:Top 8 Developed Anti-Hypertensive Therapeutics Markets Discussed in New GBI Research Report Published at MarketPublishers.com 3Health News:How the Candidates for the 2016 Presidential Election Rank in Health and Fitness 2Health News:How the Candidates for the 2016 Presidential Election Rank in Health and Fitness 3Health News:HealthSource Chiropractic Franchise Expands National Footprint as Investors Buy In 2Health News:HealthSource Chiropractic Franchise Expands National Footprint as Investors Buy In 3Health News:#BeautyChangesLives Legacy Award Pays Tribute to Industry Icon Leo Passage 2Health News:#BeautyChangesLives Legacy Award Pays Tribute to Industry Icon Leo Passage 3Health News:Tom Fleming named Chairman of the Board and Robert Casares as Vice-Chairman of the Board of LinkToBanking 2Health News:Tom Fleming named Chairman of the Board and Robert Casares as Vice-Chairman of the Board of LinkToBanking 3
... as likely as whites or Hispanics to develop condition ... are almost twice as likely to develop severe sepsis ... severe sepsis than either whites or Hispanics, new research ... the bloodstream accompanied by acute organ dysfunction. The study, ...
... Warwick and the Indian Institute of Technology Kanpur have discovered ... safely through our blood stream can, in certain circumstances, collapse ... lines of iron rust. This process could provide the first ... cause some forms of Parkinsons & Alzheimers and Huntingtons diseases. ...
... Congresswoman,Stephanie Tubbs Jones announced that six new construction ... Stokes Cleveland VA Medical,Center by the Department of ... made possible by a $397 million increase over ... final 2008,Appropriations bill signed into law in December., ...
... announced third quarter and nine months results for fiscal,2008. ... sales,increased 30.9% to $48.5 million versus $37.0 million for ... quarter was $1.5 million, equal to $0.15 per,diluted share, ... share,for the third quarter of fiscal 2007., For ...
... Mesa Laboratories,Inc. (Nasdaq: MLAB ) today announced ... quarterly cash dividend of ten cents per share ... shareholders of record at the close of,business on ... manufactures and markets,electronic instruments for industrial, pharmaceutical and ...
... can occur in patients (both children and adults) ... they have been pre-medicated with corticosteroids and antihistamines, ... at the University of Michigan Health Systems in ... at our institution who have a history of ...
Cached Medicine News:Health News:Blacks More Likely to Die of Severe Sepsis 2Health News:Iron banded worms drying out of blood could be linked to Parkinson's and Alzheimer's 2Health News:Hawkins, Inc. Reports Third Quarter, Nine Months Fiscal 2008 Results 2Health News:Hawkins, Inc. Reports Third Quarter, Nine Months Fiscal 2008 Results 3Health News:Hawkins, Inc. Reports Third Quarter, Nine Months Fiscal 2008 Results 4Health News:Allergic-like reactions occur in premedicated patients 2
(Date:3/26/2015)... 2015 According to a new ... Technology (RF, Microwave, Cryoablation, Others), Department (Interventional Radiology, Surgery, ... Metastasis) - Global Forecasts to 2019", published by MarketsandMarkets, ... $462.0 Million growing at a CAGR of 11.50% by ... 57 figures spread through 195 pages and in-depth TOC ...
(Date:3/26/2015)... , March 26, 2015  CCS Medical ("CCS"), ... medical supplies for patients with chronic conditions, has ... Chief Executive Officer, effective March 23.  Mr. Carson ... company, where he was President of Operations. ... President and Executive Vice President of Operations at ...
(Date:3/26/2015)... 26, 2015  Desert Valley Medical Center, named a ... is the first U.S. hospital to deploy the ... to help clinicians prevent hospital acquired pressure ulcers. ... , is a community hospital serving some higher ... Leaf Patient Monitor in the hospital,s emergency department enables ...
Breaking Medicine Technology:Tumor Ablation Market Worth $462.0 Million by 2019 2Tumor Ablation Market Worth $462.0 Million by 2019 3Tumor Ablation Market Worth $462.0 Million by 2019 4CCS Medical Team Hires Industry Operator Rodney Carson as CEO 2Desert Valley Medical Center First to Use Leaf Healthcare Patient Wearable Technology in its ED as Part of Hospital-wide Deployment 2Desert Valley Medical Center First to Use Leaf Healthcare Patient Wearable Technology in its ED as Part of Hospital-wide Deployment 3
... landmark trial provide important insight for physicians in treating ... Corporation (NYSE: BSX ) today welcomed the ... this week,s issue of the New England Journal of ... Cardiovascular Research Foundation with research grant support from Boston ...
... over linezolid in resistance acquisition by Staph aureus ... meetingSAN DIEGO, Calif., May 6 Trius Therapeutics, ... the treatment of serious bacterial infections, announced today ... lead program, torezolid (TR-701), will be presented in ...
Cached Medicine Technology:Boston Scientific Welcomes Publication of HORIZONS AMI Trial Results in New England Journal of Medicine 2Boston Scientific Welcomes Publication of HORIZONS AMI Trial Results in New England Journal of Medicine 3Boston Scientific Welcomes Publication of HORIZONS AMI Trial Results in New England Journal of Medicine 4Boston Scientific Welcomes Publication of HORIZONS AMI Trial Results in New England Journal of Medicine 5Trius Therapeutics Announces Presentations Featuring Torezolid Antibiotic at the 19th European Congress of Clinical Microbiology and Infectious Diseases 2Trius Therapeutics Announces Presentations Featuring Torezolid Antibiotic at the 19th European Congress of Clinical Microbiology and Infectious Diseases 3
CritiCool™ offers precise cooling to the programmed target temperature by applying temperature control algorithm....
Inquire...
Whole blood tube use for microbiology...
BD Vacutainer® Specialty Tubes - Other - Glass...
Medicine Products: